Pharmaceutical industry
MethylGene Inc., a clinical-stage biopharmaceutical company, has initiated its Phase II program for its multi-targeted kinase inhibitor, MGCD265, in combination with two approved anticancer agents, Tarceva and docetaxel. This trial aims to evaluate the safety and efficacy of MGCD265 in patients with advanced metastatic malignancies and non-small cell lung cancer
Pharmaceutical industry
GlaxoSmithKline's attempt to bring to market a rival to Roche's leading blood cancer drug, Rituxan, has suffered a significant setback. A clinical trial of Arzerra, developed by Genmab and backed by Glaxo, showed disappointing results, with only 10% of patients with non-Hodgkin's lymphoma responding
Pharmaceutical industry
The UK pharmaceutical sector is a significant contributor to the country's economy, with both primary and secondary production playing crucial roles in the industry. Primary pharmaceutical production involves the production of active pharmaceutical ingredients (API), mainly carried out by large multinational groups. These companies include GlaxoSmithKline plc, Pfizer
Pharmaceutical industry
Anadys Pharmaceuticals Inc. (ANDS), a developer of novel therapies for the treatment of hepatitis C, has garnered attention from pharmaceutical companies and investors alike. The Company's lead candidate, ANA598, a non-nucleoside polymerase inhibitor, has shown promise in its phase II trial, with initial results expected by the fourth
Pharmaceutical industry
Human Genome Sciences, Inc. (NASDAQ:HGSI) and GlaxoSmithKline PLC (GSK) announced that BENLYSTA, formerly known as LymphoStat-B, has achieved the primary endpoint in the BLISS-52 pivotal Phase 3 trial for patients with serologically active systemic lupus erythematosus (SLE). The results of the placebo-controlled study showed a clinically and statistically significant
Pharmaceutical industry
Somaxon Pharmaceuticals Inc. (SOMX), a specialty pharmaceutical company, has recently undergone an investment report by BeaconEquity.com, which includes financial, comparative, and investment analyses, as well as relevant industry information. The report focuses on Somaxon's lead drug candidate, Silenor (doxepin), which has completed four phase III clinical trials
Pharmaceutical industry
Research and Markets has released a comprehensive global strategic business report analyzing the bioterrorism market, providing insights into its dynamics, trends, and market size. The report, which covers the period from 2001 to 2015, offers a detailed analysis of the worldwide markets for bioterrorism in millions of US dollars. The
Pharmaceutical industry
Maryland's biotech industry may be impacted by proposed legislation aimed at making biologic treatments, such as antibodies and vaccines, more affordable to consumers. MedImmune Inc., a biotech company with a Frederick manufacturing center, is speaking out about the potential effects of the legislation on their business. The company&
Pharmaceutical industry
Teva Pharmaceutical Industries Ltd. has completed a $13.5 million investment in Andromeda Biotech Ltd., securing a worldwide exclusive license to commercialize DiaPep277, a potential treatment for Type 1 diabetes. The investment marks a significant milestone in the development of DiaPep277, which is currently in Phase III clinical studies. This
Pharmaceutical industry
Xtremepicks.com, a leading resource for evaluating investment opportunities in small and microcap stocks, has profiled several companies in its alert for Tuesday, June 30, 2009. Geron Corporation (Nasdaq:GERN), Vical Incorporated (Nasdaq:VICL), XenoPort, Inc. (Nasdaq:XNPT), Compugen Ltd. (NASDAQ:CGEN), and Halifax Corporation of Virginia (NYSE Amex: HX)
Pharmaceutical industry
The US biotechnology industry is a significant player in the global market, with over 1,000 companies generating combined annual revenue of nearly $50 billion. Large companies such as Amgen, Biogen Idec, Genentech, Genzyme, Life Technologies, and Monsanto have established themselves as leaders in the industry. The biotechnology and pharmaceutical
Pharmaceutical industry
CureTech Ltd., a subsidiary of Clal Biotechnology Industries Ltd. (CBI), has secured FDA approval for a Phase II clinical trial to study the efficacy of its flagship product in treating non-Hodgkin's lymphoma. The company's antibody-based treatment, which stimulates an anti-cancer immune response, will be administered in
